Loading company…
Sperogenix Therapeutics develops and commercializes medicines for rare diseases in China.
Sperogenix Therapeutics develops rare disease medicines through clinical and commercial development, including products for pulmonary hypertension, myasthenia gravis, and neurological and genetic metabolic diseases. Founded in 2015 and based in Beijing, China, the company was founded by CEO Yan Zhiyu. It closed a Series B funding round in October 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in